Ad-TK (Gencell)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameAd-TK (Gencell)

Drug Alias Nameoncolytic adenovirus therapy expressing thymidine kinase (Gencell)suicide gene therapy (RPR Gencell)Ad-TK (RPR Gencell)suicide gene therapy (Aventis Gencell)

ClassificationBiologics > Oncolytic virus

Mechanisms of ActionImmunostimulants

TargetsUpdating

Therapy Area/IndicationsBrain Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCentelion SAS

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCentelion SAS

Active IndicationsN/A

Inactive IndicationsBrain Neoplasms

Other Information

ATC CodeN/A